Sanofi
Sanofi pays $700m to expand rare disease portfolio
January 13, 2014Research and Development, Sales and Marketing Alnylam, Sanofi, rare sidease
Sanofi and Alnylam have announced the expansion of their 2012 agreement to develop and sell treatments for rare genetic diseases. …
GSK and Sanofi expand transparency
January 6, 2014Research and Development, Sales and Marketing GSK, Goldacre, Sanofi, alltrials, transparency
GlaxoSmithKline and Sanofi have announced separate moves which will shine greater light on both companies’ clinical trial data. GSK has …
Sanofi escapes most serious censure
December 13, 2013Medical Communications, Sales and Marketing ABPI, Lyxumia, PMCPA, Sanofi, censure
Sanofi has been cleared of the most serious breach of the ABPI Code of Practice – despite appearing to offer …
Priority review for Gaucher drug
December 12, 2013Sales and Marketing EMA, FDA, Gaucher, Genzyme, Sanofi
The FDA is to conduct a speedy investigation into Sanofi’s twice-daily oral candidate for Gaucher disease, which means that Cerdelga …
NICE wants more Lemtrada data
December 6, 2013Sales and Marketing Lemtrada, MS, NICE, Sanofi
NICE has said there are ‘still questions to be answered’ over Sanofi’s submission of its multiple sclerosis drug Lemtrada and …
New insulin scores for Sanofi
December 5, 2013Research and Development, Sales and Marketing Lantus, Sanofi, diabetes, u300
Sanofi has been cheered after late-stage results from its investigational insulin U300 showed that the product may have advantages over …
Third failure for Sanofi/Merrimack cancer drug
November 27, 2013Research and Development, Sales and Marketing Cancer, Sanofi, merrimack, mm-121
Sanofi and partner Merrimack have posted yet more disappointing results for their investigational cancer medicine MM-121. In the latest study …
Sanofi discards blood cancer drug in late-stage
November 19, 2013Research and Development, Sales and Marketing Sanofi, Wernicke's encephalopathy, fedratinib
Sanofi has scrapped its regulatory filing plans and late-stage trials for rare bone marrow cancer treatment fedratinib. The reason given …
Sanofi to produce weight-loss drug for Orexigen
November 11, 2013Manufacturing and Production, Sales and Marketing Contrave, FDA, Sanofi, orexigen
Sanofi has agreed a deal to manufacture Orexigen Therapeutics’ weight-loss candidate Contrave outside North America. Under the commercial supply agreement, …
‘Fatal’ safety concerns throw doubt on Lemtrada
November 11, 2013Research and Development, Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi
An FDA committee has dashed hopes of an approval for Sanofi’s multiple sclerosis drug after saying its benefits may not …
Sanofi cuts earnings guidance despite return to sales growth
October 31, 2013Sales and Marketing Sanofi, Viehbacher, vaccines
Sanofi cut its earnings guidance for 2013 after its third quarter results missed targets, despite a return – barely – …
PMCPA: Sanofi ‘discredited pharma’
October 28, 2013Medical Communications, Sales and Marketing ABPI, PMCPA, Sanofi, breach
Sanofi has lowered the public’s confidence in the pharma industry, according to the PMCPA, which enforces the ABPI Code of …
Sanofi launches ‘Monster Manor’ diabetes app
October 23, 2013Medical Communications Gamification, Sanofi, diabetes, monster manor
Sanofi has launched a new healthcare app called Monster Manor to help children with type 1 diabetes better manage their …
Sanofi appoints senior vice president
October 10, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, warnery
Vincent Warnery has been appointed as the senior vice president to Sanofi’s new Global Consumer Healthcare Division. He will remain …
Latest content
Five Facts about cardiovascular disease
